Researching the Effect of Exercise on Cancer

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Oct 9, 2020

Keywords

ClinConnect Summary

This clinical trial is studying how exercise may help prevent cancer from returning in people who have already been treated for breast, prostate, or colorectal cancer. Researchers want to see if aerobic exercise—like brisk walking, swimming, or cycling—can lower levels of ctDNA, which are tiny pieces of genetic material in the blood that can indicate cancer presence. By finding out the best amount of exercise that is safe and beneficial, the study hopes to understand how staying active might protect against cancer recurrence.

To participate in this trial, individuals must be 18 years or older and have previously been diagnosed with certain high-risk stages of breast, prostate, or colorectal cancer. They should also not be currently engaging in much exercise (less than 30 minutes of moderate activity per week) and must be cleared by a health professional to take part. Participants can expect to follow a structured exercise program, and their progress will be monitored throughout the study. This research could provide important insights into how exercise might improve long-term health for cancer survivors.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Postsurgical diagnosis of patients with primary solid tumors at high-risk of relapse as defined by one of the following:
• • ° High-risk primary solid tumor (e.g., colorectal, ovarian, non-small cell lung cancer) (colorectal cancer only for Phase 1a)
• • Stage 3 or
• • ctDNA positive
• • ° High-risk breast cancer
• • Residual invasive disease in the breast or the lymph nodes following completion of neoadjuvant chemotherapy (NACT),
• • Estrogen receptor (ER), and/or progesterone receptor (PR) positive and HER2 negative,
• • CPS-EG score ≥ 3,
• • CPS-EG score ≥2 w ith ypN+, or
• • Recurrence score ≥ 25
• • No evidence of disease
• • Age ≥ 18
• • Interval of ≥ 1 month but ≤ 2 years following completion of all definitive adjuvant therapy
• • Non-exercising (i.e., \< 30 minutes of moderate and \< 20 mins of vigorous exercise/wk), as assessed by remote activity and heart rate tracking for a 7-day period prior to study entry)
• • ° If ≥ 30 minutes but less than 45 minutes of moderate exercise/week, or if ≥ 20 minutes but less than 30 minutes of vigorous exercise/week, patients may be eligible, at the discretion of the PI.
• • Cleared for exercise participation as per screening clearance via PAR-Q+
• • Willingness to comply with all study-related procedures
• Exclusion Criteria:
• • Enrollment onto any other interventional investigational study except interventions determined by the PI not to confound study outcomes
• • Any other current diagnosis of invasive cancer of any kind
• • Distant metastatic malignancy of any kind
• • Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation